Evidence map›Paper›PMID 38474318›Full record

ArticleInternational journal of molecular sciences2024

Tung-Ho Wu, Tung-Yi Lin, Pei-Ming Yang, Wen-Tai Li, Chau-Ting Yeh, Tai-Long Pan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Recent advances inHeliyon · 2024
    Review
  5. Frontiers in pharmacology · 2024
    Review
  6. Article
  7. Research Progress ofIntegrative cancer therapies
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Tung-Ho WuSurgical Critical Care Division of Cardiovascular Surgical Department, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
Tung-Yi LinDepartment of Traditional Chinese Medicine, Chang Gung Memorial Hospital at Keelung, Keelung 204, Taiwan.ORCID 0000-0001-6495-7221
Pei-Ming YangTMU Research Center of Cancer Translational Medicine, Taipei 110, Taiwan.ORCID 0000-0002-4004-2518
Wen-Tai LiNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei 112, Taiwan.
Chau-Ting YehLiver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Tai-Long PanLiver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.ORCID 0000-0002-0187-8689
Chang Gung Memorial Hospital · TWChang Gung University of Science and Technology · TWKaohsiung Veterans General Hospital · TWKeelung Chang Gung Memorial Hospital · TWNational Research Institute of Chinese Medicine · TWTaipei Medical University · TW

Funding

Chang Gung Memorial Hospital CMRPD1M0641, BMRP445National Science and Technology Council MOST-111-2320-B-182-014, NSTC112-2320-b-182-026
6 · The paper itself

Abstract

Hepatocellular carcinoma is one of the most common malignant tumors in the world and shows strong metastatic potential. Current medicine for hepatocellular carcinoma therapy is invalid, while

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPlant ExtractsScutellaria baicalensisApoptosisHumansTumor Suppressor Protein p53Plant ExtractsScutellaria baicalensis extractTumor Suppressor Protein p53apoptosiscell cyclehepatocellular carcinomaHSP90βmetastasisScutellaria baicalensis

Identifiers

PMID38474318
PMCPMC10932101
OpenAlexW4392554025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.